$EIKN earnings report

Eikon reports Q3 2026 net loss of $86.1 million as R&D expense rises 21%; cash of $461.7 million supports runway into Q1 2028. AlphAI read Eikon Therapeutics's Q3 FY2026 filing as mixed. 2 quarters are on record below.

Q3 FY2026

AlphAI · Earnings readEIKN · Q3 2026 · ended 2026-09-30

Eikon reports Q3 2026 net loss of $86.1 million as R&D expense rises 21%; cash of $461.7 million supports runway into Q1 2028

→Mixed quarter

The release reports no revenue. Operating expenses and net loss both widened year over year, with R&D up 21% for the quarter. Offsetting this, the company reports $461.7 million in cash, a runway guidance extension into Q1 2028, and several clinical and regulatory milestones, including an IND submission for EIK1006.

EPS · GAAP
$(1.59)

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Research and development expenses, three months ended Sept 30, 2026GAAP$71.83M–increase of $12.5 million, or 21%
General and administrative expenses, three months ended Sept 30, 2026GAAP$18.73M–increase of $3.3 million, or 21%
Total operating expenses, three months ended Sept 30, 2026GAAP$90.55M––
Loss from operations, three months ended Sept 30, 2026GAAP−$90.55M––
Interest income (expense), net, three months ended Sept 30, 2026GAAP$4.49M––
Other income (expense), net, three months ended Sept 30, 2026GAAP−$46K––
Net loss and comprehensive loss, three months ended Sept 30, 2026GAAP−$86.11M––
Net loss attributable to common stockholders, three months ended Sept 30, 2026GAAP$86.1 million net loss––
Net loss per share attributable to common stockholders, basic and diluted, three months ended Sept 30, 2026GAAP$(1.59)––
Research and development expenses, nine months ended Sept 30, 2026GAAP$217.3M––
General and administrative expenses, nine months ended Sept 30, 2026GAAP$53.95M–down 24%
Total operating expenses, nine months ended Sept 30, 2026GAAP$271.3M–increased 6%
Loss from operations, nine months ended Sept 30, 2026GAAP−$271.3M––
Interest income (expense), net, nine months ended Sept 30, 2026GAAP$13.90M––
Other income (expense), net, nine months ended Sept 30, 2026GAAP−$99K––
Net loss and comprehensive loss, nine months ended Sept 30, 2026GAAP−$257.5M––
Impact of preferred stock extinguishments and modifications, nine months ended Sept 30, 2025GAAP−$9.40M––
Net loss attributable to common stockholders, nine months ended Sept 30, 2026GAAP−$257.5M––
Net loss per share attributable to common stockholders, basic and diluted, nine months ended Sept 30, 2026GAAP$(5.43)––
Cash, cash equivalents and marketable securities, as of Sept 30, 2026other$461.7M––
Total assets, as of Sept 30, 2026other$706.2M––
Total liabilities, as of Sept 30, 2026other$321.9M––
Total stockholders' equity (deficit), as of Sept 30, 2026other$384.3M––
Net cash used in operating activities, nine months ended Sept 30, 2026other$224M––

Capital returns

  • The filing reports no share repurchases and no dividends for the period.

What drove it

  • R&D expenses rose $12.5 million, or 21%, to $71.8 million. The company states that direct R&D expenses increased $9.2 million as it advanced its clinical trial activity, and compensation costs increased $3.0 million.
  • G&A expenses rose $3.3 million, or 21%, to $18.7 million. The company states this was primarily due to $1.5 million higher professional fees from consulting and legal expenses and $1.1 million higher other operating expenses, primarily IT expenses.
  • For the nine months, the CFO states total operating expenses increased 6% year over year, G&A decreased 24%, and R&D represented 80% of the total.
  • Clinical activity in the period included EIK1001 data at ESMO (TeLuRide-005, pooled ORR 63.1%, n=65), first patient dosed in TeLuRide-008 (July 27, 2026), EIK1003 and EIK1004 Phase 1/2 data at ESMO, EIK1005 preliminary data, and an IND submitted for EIK1006 (Oct 14, 2026).
  • The company states that it is concentrating investment behind its most advanced programs and tying incremental spending to clinical milestones.

Concerns

  • Net loss attributable to common stockholders widened to $86.1 million from $71.1 million in the prior-year quarter.
  • Operating expenses rose in both the quarter and the nine months, with R&D up 21% in the quarter.
  • Net cash used in operating activities was $224.0 million over nine months, against $461.7 million of cash at quarter end.
  • The release reports no revenue line and no numeric financial guidance, so the runway statement is the only forward financial figure.
  • Several efficacy results cited are from small cohorts and single-arm settings, for example EIK1003 monotherapy ORR of 14.3% across 49 efficacy-evaluable participants and EIK1005 preliminary data from a limited number of participants.

What to watch

  • Interim analysis for advancement to Phase 3 in TeLuRide-006 (EIK1001 in advanced melanoma), anticipated in the first half of 2027.
  • Interim analysis for dose selection in TeLuRide-008, anticipated in the second half of 2027.
  • Additional EIK1005 results from the combination study with pembrolizumab, expected in the first half of 2027.
  • Initial EIK1003 Cohort 1D results with paclitaxel and platinum-based chemotherapy, expected in the second half of 2027.
  • Initial results from the EIK1004 combination arm with docetaxel in castrate-resistant prostate cancer, expected in the second half of 2027.
  • Preliminary EIK1006 safety and efficacy data, expected in the second half of 2027, subject to FDA clearance to start the Phase 1/2 study.
  • Whether cash of $461.7 million continues to support operations into Q1 2028 as operating spend rises.

Balance sheet and cash flow

  • Cash, cash equivalents and marketable securities were $461,717 thousand at Sept 30, 2026, compared with $335,975 thousand at Dec 31, 2025.
  • Total assets were $706,201 thousand at Sept 30, 2026, compared with $594,734 thousand at Dec 31, 2025.
  • Total liabilities were $321,908 thousand at Sept 30, 2026, compared with $312,298 thousand at Dec 31, 2025.
  • Total stockholders' equity was $384,293 thousand at Sept 30, 2026, compared with a deficit of $(879,034) thousand at Dec 31, 2025.
  • Net cash used in operating activities was $224.0 million for the nine months ended Sept 30, 2026. The filing does not print the comparable prior-year figure.
  • Eikon expects its current cash, cash equivalents, and marketable securities to fund operations into the first quarter of 2028.

Analysis

Eikon reported a third-quarter 2026 net loss attributable to common stockholders of $86.1 million, compared with $71.1 million in the prior-year quarter, and EPS of $(1.59) against $(24.24). The release contains no revenue line, so the read is driven entirely by expenses and the balance sheet. Total operating expenses for the quarter were $90,552 thousand, against $74,751 thousand a year earlier. R&D expense was $71,826 thousand, up 21%, and the company attributes the increase to advancing clinical trial activity and higher compensation costs. G&A expense was $18,726 thousand, up 21%, which the company attributes mainly to higher professional fees and IT expenses.

Over the nine months, the picture differs by line. Total operating expenses were $271,283 thousand, which the CFO describes as an increase of 6% year over year. G&A for the nine months was $53,950 thousand, which the CFO describes as down 24%, while R&D was $217,333 thousand. Interest income, net, was $4,486 thousand for the quarter and $13,903 thousand for the nine months, and it offset part of the operating loss in the net loss line. The filing prints no prior-quarter (June 30, 2026) figures, so sequential comparisons are not available from this document.

On the balance sheet, cash, cash equivalents and marketable securities were $461,717 thousand at September 30, 2026, up from $335,975 thousand at December 31, 2025. Stockholders' equity moved from a deficit of $(879,034) thousand to $384,293 thousand over the same span. The filing does not state the source of that change, so the reader should review the 10-Q for the cause. Net cash used in operating activities was $224.0 million for the nine months. Management updated runway guidance to fund operations into the first quarter of 2028.

Clinical disclosures are the bulk of the release. EIK1001 in TeLuRide-005 reported a pooled ORR of 63.1% and DCR of 89.2% across 65 efficacy-evaluable patients, with squamous and non-squamous cohorts reported separately. EIK1003 monotherapy reported an ORR of 14.3% across 49 participants, with 31.3% among PARP inhibitor-naive participants. EIK1004 reported an ORR of 12.1% across 58 participants. These are early and small-cohort data. The milestone calendar places multiple interim analyses in 2027, including the TeLuRide-006 Phase 3 advancement decision and the TeLuRide-008 dose-selection analysis.

The release provides no numeric financial guidance and no prior outlook to compare against, so the vs_prior_guidance list is empty. The only forward financial statement is the runway into the first quarter of 2028, and the filing does not print the prior runway date.

Management, verbatim

We ended the third quarter with $461.7 million in cash and are updating our runway guidance into the first quarter of 2028, through the key clinical milestones anticipated in 2027.

Freddie Bowie, Ph.D., Chief Financial Officer

We are concentrating investment behind our most advanced programs and tying incremental spending to clinical milestones, with the goal of creating long-term shareholder value.

Freddie Bowie, Ph.D., Chief Financial Officer

The third quarter was marked by important progress across Eikon's oncology programs.

Roger M. Perlmutter, M.D., Ph.D., Chief Executive Officer and Board Chair

Not in the filing

stated, not guessed
  • Revenue or collaboration revenue for the three and nine months: the filing prints no revenue line.
  • Gross margin and cost of sales: not reported.
  • Prior-quarter (June 30, 2026) figures for all income statement and balance sheet lines: not printed.
  • Prior-year nine-month net cash used in operating activities: not printed.
  • Three-month net cash used in operating activities: not printed.
  • Prior-year cash balance at Sept 30, 2025: not printed (only the Dec 31, 2025 balance is given).
  • Percentage change for the net loss lines: not printed.
  • Percentage change for total operating expenses in the three-month period: not printed.
  • Prior runway guidance date: not printed, so the change in runway cannot be measured.
  • Source of the increase in stockholders' equity from deficit to positive equity: not stated in the release.
  • Numeric financial guidance for 2026 or 2027: not provided.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Second Quarter 2026

AlphAI · Earnings readEIKN · Second Quarter 2026 · ended June 30, 2026

Eikon Therapeutics Reports Second Quarter 2026 Financial Results and Provides Clinical Updates

→Mixed quarter

Eikon advanced multiple clinical programs and ended the quarter with $531.2 million in cash, cash equivalents and marketable securities, but remained pre-revenue in the reported financial information and recorded a net loss attributable to common stockholders of $88.4 million.

EPS · GAAP
$(1.63)

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Research and development expensesGAAP$75.5M–9%
General and administrative expensesGAAP$17.9M–56%
Total operating expensesGAAP$93.39M––
Loss from operationsGAAP−$93.39M––
Interest income (expense), netGAAP$5.04M––
Other income (expense), netGAAP−$52K––
Net loss and comprehensive lossGAAP−$88.41M––
Net loss attributable to common stockholdersGAAP$88.4M––
Net loss per share attributable to common stockholders, basic and dilutedGAAP$(1.63)––
Weighted-average shares of common stock outstanding used in computing net loss per share attributable to common stockholders, basic and dilutedGAAP54,143,162––
Research and development expenses, six months ended June 30GAAP$145.5M––
General and administrative expenses, six months ended June 30GAAP$35.22M––
Total operating expenses, six months ended June 30GAAP$180.7M––
Loss from operations, six months ended June 30GAAP−$180.7M––
Interest income (expense), net, six months ended June 30GAAP$9.42M––
Other income (expense), net, six months ended June 30GAAP−$53K––
Net loss and comprehensive loss, six months ended June 30GAAP−$171.4M––
Impact of preferred stock extinguishments and modifications, six months ended June 30GAAP—––
Net loss attributable to common stockholders, six months ended June 30GAAP−$171.4M––
Net loss per share attributable to common stockholders, basic and diluted, six months ended June 30GAAP$(3.90)––
Weighted-average shares of common stock outstanding used in computing net loss per share attributable to common stockholders, basic and diluted, six months ended June 30GAAP43,978,373––
Cash, cash equivalents and marketable securitiesGAAP$531.2M––
Total assetsGAAP$779.6M––
Total liabilitiesGAAP$313.1M––
Total stockholders’ equity (deficit)GAAP$466.5M––

Amounts quoted below without a unit are in thousands, as in the filing’s tables. Per-share figures are as printed.

into the second half of 2027 outlook

  • NoteEikon expects its current cash, cash equivalents, and marketable securities to fund operations into the second half of 2027.

What drove it

  • Direct research and development expenses increased by $12.8 million as Eikon advanced its clinical trial activity.
  • Compensation costs increased by $1.7 million.
  • The first interim analysis of the TeLuRide-006 Phase 2/3 registrational trial was completed, with the independent Data Monitoring Committee selecting a single dosing regimen for expansion and recommending that the study continue as planned.
  • Eikon dosed the first patient in TeLuRide-008, a Phase 2/3 registrational trial of EIK1001 in first-line treatment-naive stage 4 NSCLC.
  • Eikon expects presentations of clinical data for EIK1001, EIK1003, EIK1004 and EIK1005 at the ESMO Congress 2026.

Concerns

  • Net loss attributable to common stockholders was $88.4 million for the second quarter of 2026.
  • R&D expenses increased 9% to $75.5 million as clinical trial activity advanced.
  • The filing reports no revenue, gross profit, gross margin, operating cash flow or free cash flow.
  • Eikon states that it has incurred significant net losses since inception and expects to incur additional losses for the foreseeable future.
  • The clinical candidates remain subject to development, regulatory and funding risks described in the forward-looking statements.

What to watch

  • Full TeLuRide-005 combination data in NSCLC on Monday, October 26 at ESMO.
  • Updated EIK1003 Phase 1/2 monotherapy and combination data across Cohorts 1A, 1B and 1C on Friday, October 23 at the ESMO Congress 2026.
  • Initial Phase 1/2 data for EIK1004 and EIK1005 on Friday, October 23 at the ESMO Congress 2026.
  • Eikon expects to submit an investigational new drug application for EIK1006 by the end of 2026.
  • Execution against the stated expectation that current cash, cash equivalents and marketable securities will fund operations into the second half of 2027.

Balance sheet and cash flow

  • As of June 30, 2026, Eikon had cash, cash equivalents, and marketable securities of $531.2 million.
  • Cash, cash equivalents and marketable securities were $531,178 (in thousands) as of June 30, 2026, compared to $335,975 (in thousands) as of December 31, 2025.
  • Total assets were $779,570 (in thousands) as of June 30, 2026, compared to $594,734 (in thousands) as of December 31, 2025.
  • Total liabilities were $313,070 (in thousands) as of June 30, 2026, compared to $312,298 (in thousands) as of December 31, 2025.
  • Total stockholders’ equity (deficit) was $466,500 (in thousands) as of June 30, 2026, compared to $(879,034) (in thousands) as of December 31, 2025.

Analysis

Eikon reported a development-stage quarter centered on clinical execution rather than commercial performance. The financial statements report no revenue line, while the company recorded a GAAP net loss attributable to common stockholders of $88.4 million. Research and development expense rose 9% to $75.5 million as direct research and development expense increased by $12.8 million in connection with advancing clinical trial activity, with compensation costs also increasing by $1.7 million.

The operating-expense mix improved versus the year-ago period because G&A expense declined 56% to $17.9 million. Management attributed this reduction primarily to the prior-year impairment of $10.7 million of property and equipment and $10.3 million of operating lease right-of-use assets related to Hayward properties vacated in April 2025. Total operating expenses were $93,394 (in thousands), compared with $109,643 (in thousands) in the prior-year period, while loss from operations was $(93,394) (in thousands).

Clinical progress was the central operating development. The TeLuRide-006 interim analysis led the independent Data Monitoring Committee to select a single dosing regimen for expansion and recommend continuation of the trial as planned. Eikon also began dosing in TeLuRide-008 and plans ESMO presentations for all four current clinical candidates, including full TeLuRide-005 combination data in NSCLC and initial data for EIK1004 and EIK1005. The filing does not provide prior-quarter financial comparisons, so quarter-over-quarter changes are not reported.

Liquidity was $531.2 million in cash, cash equivalents and marketable securities at June 30, 2026, and the company expects these resources to fund operations into the second half of 2027. The balance sheet reported $779,570 (in thousands) of total assets, $313,070 (in thousands) of total liabilities and $466,500 (in thousands) of total stockholders’ equity. The key financial watch item is the pace of R&D spending as multiple registrational and early-stage clinical programs advance, while the key operating watch items are the October ESMO disclosures and the anticipated EIK1006 IND submission by the end of 2026.

Management, verbatim

The second quarter saw meaningful acceleration of Eikon’s most important clinical programs, leading to acceptance of seven abstracts, related to all four of our current clinical candidates, for presentation at the upcoming ESMO conference in October in Madrid.

Roger M. Perlmutter, M.D., Ph.D., Chief Executive Officer and Board Chair of Eikon Therapeutics

Our strong balance sheet enables us to continue to support an increasingly mature pipeline, including ongoing registrational studies of EIK1001 in both advanced melanoma and non-small cell lung cancer.

Freddie Bowie, Ph.D., Chief Financial Officer

Not in the filing

stated, not guessed
  • Total revenue
  • Revenue comparisons and growth rates
  • Revenue by segment
  • Gross profit
  • Gross margin
  • Operating income
  • GAAP income tax expense or benefit
  • GAAP effective tax rate
  • Non-GAAP financial metrics
  • Operating cash flow
  • Free cash flow
  • Debt
  • Share repurchases
  • Dividends
  • Prior-quarter financial comparisons
  • Revenue guidance
  • Gross margin guidance
  • Operating expense guidance
  • Tax-rate guidance
  • Previous-quarter outlook for comparison

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Questions about EIKN earnings dates

When is Eikon Therapeutics's next earnings date?
AlphAI has no date for EIKN yet. We do not publish estimates, so this page shows a date the day we have one.
Why is there sometimes no date?
AlphAI leaves out estimates. Many sites fill the gap by adding about 91 days to the last report, but that arithmetic is a guess, and a wrong date costs a reader more than a missing one, so we show nothing until a date is set, and a company can still move it. Every quarter already on this page is read straight from the SEC filing: an 8-K item 2.02 for US filers, a 6-K earnings release for foreign private issuers.